Guide to Alkaline Phosphatase (ALP)

WRITTEN BY

Updated: 05/22/2025|12 min read

Summary

Alkaline phosphatase (ALP) is an enzyme found throughout the body. The highest concentrations are in the liver, bile duct, bones, kidneys, intestines, and, when pregnant, the placenta. When analyzed alongside other blood markers, ALP levels can be used as an indicator of health across different systems.

Why It Matters

Alkaline phosphatase (ALP) is an enzyme that removes phosphate groups from molecules, enabling vital processes throughout the body. This single biochemical activity serves different functions in multiple organ systems.

In bones, ALP increases local phosphate concentration by releasing phosphate from other molecules, allowing it to combine with calcium for mineralization—critical during growth periods and bone healing. In the liver and bile ducts, ALP facilitates bile flow and metabolism, with high concentrations in the cells lining bile ducts and the membranes of liver cells. In the intestines, it aids in fat absorption, maintains gut barrier function, and detoxifies bacterial endotoxins.

Unlike many biomarkers that indicate problems in just one system, ALP provides insights across multiple organs—primarily the liver and bones. In most patients with elevated ALP, the liver is the primary source, making it valuable for diagnosing cholestatic liver disease (where bile flow is blocked). The next most common contributor is increased bone cell activity during growth or bone disorders. Pregnant women in the third trimester also experience temporarily high ALP due to placental production. Conversely, low ALP can indicate zinc deficiency, protein malnutrition, or hypothyroidism.

Because ALP exists in different forms (isoenzymes) specific to different tissues, additional testing can often determine which organ system is causing abnormal levels, making it a valuable diagnostic clue that directs further investigation.

Associated Symptoms

Alkaline phosphatase levels themselves are laboratory findings rather than medical conditions. However, abnormal levels may be associated with various health conditions, each with their own symptoms.

Common symptoms that may indicate liver conditions associated with elevated ALP:

Right upper quadrant abdominal pain: May indicate bile duct obstruction or liver inflammation
Fatigue: Common with many liver disorders due to metabolic disruptions
Itching (pruritus): Can result from bile salts depositing in the skin when bile flow is obstructed
Yellowing of skin or eyes (jaundice): Occurs when bilirubin builds up due to bile duct blockage
Nausea and loss of appetite: Can accompany liver dysfunction
Easy bruising or bleeding: May result from impaired clotting factor production in severe liver disease

Common symptoms that may indicate bone conditions associated with elevated ALP:

Bone pain: May occur in conditions like Paget's disease or metastatic bone cancer
Joint pain and inflammation: Can occur with bone disorders affecting nearby joint structures
Fractures with minimal trauma: May occur in conditions causing bone weakness despite high ALP
Bone deformities: Can be seen in severe cases of metabolic bone disease
Abnormal growth patterns: May occur in children with certain bone disorders

Symptoms that may indicate conditions associated with low ALP:

Neurological symptoms: May include anxiety, depression, or confusion in severe deficiency
Seizures: Can occur in rare genetic conditions like hypophosphatasia
Dental problems: May include premature tooth loss or dental abnormalities
Recurrent fractures: Can occur in genetic causes of low ALP

It's important to note that many conditions affecting ALP levels may be asymptomatic in early stages, which is why laboratory testing is valuable for early detection. Additionally, symptoms are typically related to the underlying condition rather than directly to the ALP level itself.

Clinical Ranges

Female:

17-19 Years: 36-128 U/L
20-49 Years: 31-125 U/L
> 49 Years: 37-153 U/L

Male:

17-19 Years: 46-169 U/L
20-49 Years: 36-130 U/L
> 49 Years: 35-144 U/L

Lifestyle Factors That Can Impact It

More than 1,000 drugs, herbs, and physiological conditions affecting ALP activity have been documented, but here are a few of the most common.

Factors that can support a healthy ALP balance include:

Lifting weights stimulates bone formation and bone metabolism
Adequate protein, vitamin D, calcium, and zinc support bone formation and enzyme activity
Regular physical activity promotes healthy bone remodeling and metabolism
Good sleep habits allow proper hormone regulation and enzyme production cycles
Stress management helps maintain healthy cortisol levels, which can affect bone metabolism and ALP production

Lifestyle factors that may negatively impact a healthy ALP balance include:

Excessive alcohol consumption can damage liver cells, leading to elevated ALP levels and impaired enzyme function
Smoking reduces bone density and interferes with calcium absorption
A sedentary lifestyle impacts bone formation
Extreme dieting can lead to nutrient deficiencies that interfere with proper enzyme production and bone metabolism
Excessive caffeine intake may interfere with calcium absorption and bone formation
Lack of sun exposure reduces vitamin D production, which is crucial for calcium absorption and proper ALP function in bone metabolism
Chronic stress elevates cortisol levels that can interfere with bone formation and enzyme production

Other Factors That Can Impact It

Genetic and Medical Conditions

Hypophosphatasia: may lead to low ALP
Wilson's disease: may lower ALP levels
Primary sclerosing cholangitis: can elevate ALP
Genetic variants affecting bone metabolism
Paget's disease: may cause high levels
Osteoporosis: can elevate ALP

Medications and Supplements

Oral contraceptives: can cause levels to fluctuate depending on the type of contraceptive and length of use
Anabolic steroids: can increase ALP
Some antibiotics: can cause higher levels of ALP
Antiepileptic drugs: can increase ALP
Hormone replacement therapy: can lower bone-specific ALP
Blood pressure medications: can raise or lower levels depending on the medication
Statins: may increase or decrease levels

Individual Factors

Age: Levels are higher in children, adolescents, and older adults.
Gender: Men and women have slightly different ranges.
Pregnancy: Levels may go up during pregnancy.
Season: Vitamin D levels from sun exposure tend to be higher during spring and summer.
Recent fractures: A broken bone can lead to higher levels as the body begins to repair the injury.

Testing Accuracy and Stability

ALP tests are generally accurate under proper testing conditions, but ALP levels can fluctuate depending on things like physical activity and what you've eaten before the test.

Factors That Can Affect the Accuracy of Your Test

If you ate a fatty meal before the test (eating can slightly increase levels, particularly in people with blood types O or B)
If you exercised strenuously within 24-48 hours of taking the test (exercise can increase levels)
Which phase of the menstrual cycle you're in (levels can vary throughout the cycle)

How it Relates to Other Markers

Your healthcare providers will compare your ALP results with other tests to better understand your overall health and diagnose conditions. Some other tests they might look at include:

Gamma-glutamyl transferase (GGT): Comparing levels of this liver enzyme with ALP helps distinguish between liver and bone conditions since GGT is not elevated in bone conditions.
Calcium: This is often evaluated alongside ALP because both are involved in bone metabolism and can indicate another condition like cancer if they're both abnormal.
Parathyroid hormone (PTH): PTH works with ALP in bone metabolism. Abnormalities in both can indicate parathyroid disorders (a dysfunction of the smaller glands within your thyroid gland).
Vitamin D: This vitamin helps ALP in bone metabolism, and a lack of vitamin D can affect ALP levels and bone health.
AST/ALT (liver enzymes): These may be used to determine if elevated ALP is due to liver disease, as they typically rise together in liver conditions.
Bilirubin: Examining this byproduct of red blood cell breakdown can help indicate liver disease or a bile duct blockage when it's evaluated with ALP.
5'-nucleotidase enzyme: It can confirm if elevated ALP is due to a liver issue when both are increased.
Bone-specific ALP: This test helps determine if elevated total ALP is from bone sources.
Phosphate: It works closely with ALP in bone metabolism, and their relationship helps diagnose various bone disorders, kidney disease, or parathyroid disorders.
25-hydroxy vitamin D: Testing for this can clarify if ALP abnormalities might be related to vitamin D insufficiency.

Follow-up Considerations

If your ALP level is abnormal, your provider may work with you on steps to address the issue. You should always talk to your doctor if you have medical concerns or questions.

When Re-Testing May be Appropriate

Mild elevation (1.5x ULN): Quarterly monitoring to start
Moderate elevation (1.5 - < 2x ULN): Repeat in 2-3 weeks
Severe elevation (≥2x ULN): Immediate retest with a comprehensive panel
Low levels: Confirm within 2 weeks
During treatment of underlying condition: Monthly until normalized
After starting new medications that affect ALP: 4-6 weeks to establish a new baseline

Additional Testing Your Doctor May Consider

Liver evaluation: GGT, bilirubin, AST/ALT, and right upper quadrant ultrasound
Bone assessment: Bone-specific ALP isoenzyme, vitamin D, calcium, and phosphate levels
For persistently elevated levels: ALP isoenzyme testing to determine the source
For low levels: Zinc levels, nutritional assessment, and thyroid function testing
In pregnant women: No additional testing needed if otherwise healthy
With severe or unexplained elevation: Imaging studies of liver and/or bones based on clinical suspicion

When Additional Care May be Warranted

Mild elevation: If persists >3 months or symptoms develop
Moderate elevation: If no improvement after 1 month
Severe elevation (≥2x ULN): Immediate specialist referral
Low levels: If nutritional intervention doesn't improve levels after 2 months

Bibliography

References

1. Sharma U, et al. (2014). Alkaline phosphatase: an overview. Indian Journal of Clinical Biochemistry, 29(3), 269-278. DOI: 10.1007/s12291-013-0408-y

2. Millán JL. (2006). Alkaline phosphatases: structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signalling, 2(2), 335-341. DOI: 10.1007/s11302-005-5435-6

3. Whyte MP. (2016). Hypophosphatasia: an overview for 2017. Bone, 102, 15-25. DOI: 10.1016/j.bone.2017.02.011.

4. Lowe D, et al. (2018). Alkaline phosphatase: a potential biomarker for stroke and implications for treatment. Metabolic Brain Disease, 33(4), 1281-1294.

5. Siddique A, Kowdley KV. (2012). Approach to a patient with elevated serum alkaline phosphatase. Clinics in Liver Disease, 16(2), 199-229. doi: 10.1016/j.cld.2012.03.012.

6. Moss DW. (1992). Perspectives in alkaline phosphatase research. Clinical Chemistry, 38(12), 2486-2492. https://doi.org/10.1093/clinchem/38.12.2486

7. Schoppet M, Shanahan CM. (2008). Role for alkaline phosphatase as an inducer of vascular calcification in renal failure? Kidney International, 73(9), 989-991. DOI: 10.1038/ki.2008.104

8. Pike AF, et al. (2013). Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD. Nature Reviews Nephrology, 9(10), 620-628. DOI: 10.1038/nrneph.2017.60.

9. Tonelli M, et al. (2009). Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation, 120(18), 1784-1792. DOI: 10.1161/CIRCULATIONAHA.109.851873.

10. Brichacek AL, Brown CM. (2019). Alkaline phosphatase: a potential biomarker for stroke and implications for treatment. Metabolic Brain Disease, 34(1), 3-19. doi: 10.1007/s11011-018-0322-3

11. Orimo H. (2010). The mechanism of mineralization and the role of alkaline phosphatase in health and disease. Journal of Nippon Medical School, 77(1), 4-12. DOI: 10.1272/jnms.77.4.

12. Cho YE, et al. (2015). Zinc deficiency and cellular oxidative stress: prognostic implications in cardiovascular diseases. Acta Pharmacologica Sinica, 36(8), 959-967.

13. Kheir MM, et al. (2018). Vitamin D deficiency and its correlation with disease activity in adult rheumatoid arthritis. Endocrine, Metabolic & Immune Disorders Drug Targets, 18(6), 537-545.

14. Mukaiyama K, et al. (2015). Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Journal of Bone and Mineral Metabolism, 33(5), 530-538. DOI: 10.1007/s40520-014-0296-x.

15. Lowe D, et al. Properties and function of alkaline phosphatase. Bone. 2017;95:8-12.

16. Fishman WH. Alkaline phosphatase isozymes: recent progress. Clinical Biochemistry. 1990;23(2):99-104. DOI: 10.1016/0009-9120(90)80019-f.

17. Navarro VJ, Senior JR. Drug-related hepatotoxicity. New England Journal of Medicine. 2006;354(7):731-739. DOI: 10.1056/NEJMra052270.

18. Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver disease. Digestive Diseases and Sciences. 1988;33(12):1601-1614. DOI: 10.1007/BF01535953.

19. Whyte MP. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocrine Reviews. 1994;15(4):439-461. DOI: 10.1210/edrv-15-4-439.

20. Millan JL, Whyte MP. Alkaline phosphatase and hypophosphatasia. Calcified Tissue International. 2016;98(4):398-416. DOI: 10.1007/s00223-015-0079-1.

21. Malagelada, JR., Linscheer, W.G. & Fishman, W.H. The effect of fatty acid perfusion on intestinal alkaline phosphatase. Digest Dis Sci 22, 516–523 (1977). DOI: 10.1007/BF01072504.

22. Alvarenga L, Cardozo LFMF, Lindholm B, Stenvinkel P, Mafra D. Intestinal alkaline phosphatase modulation by food components: predictive, preventive, and personalized strategies for novel treatment options in chronic kidney disease. EPMA J. 2020 Nov 18;11(4):565-579. DOI: 10.1007/s13167-020-00228-9.

23. Goldberg, R. F., Austen, W. G., Zhang, X., Munene, G., Mostafa, G., Biswas, S., … & Hodin, R. A. (2008). Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proceedings of the National Academy of Sciences, 105(9), 3551-3556. DOI: 10.1073/pnas.0712140105.

24. Su W, Qiu T, Zhang M, Hao C, Zeng P, Huang Z, Du W, Yun T, Xuan Y, Zhang L, Guo Y, Jiao W. Systems biomarker characteristics of circulating alkaline phosphatase activities for 48 types of human diseases. Curr Med Res Opin. 2022 Feb;38(2):201-209. https://doi.org/10.1080/03007995.2021.2000715

25. Khandwala HM, Mumm S, Whyte MP. Low serum alkaline phosphatase activity and pathologic fracture: case report and brief review of hypophosphatasia diagnosed in adulthood. Endocr Pract. 2006 Nov-Dec;12(6):676-81. DOI: 10.4158/EP.12.6.676.

26. Tournis S, Yavropoulou MP, Polyzos SA, Doulgeraki A. Hypophosphatasia. J Clin Med. 2021 Dec 1;10(23):5676 DOI: 10.3390/jcm10235676.

27. Alp, A. (2015). Bone-Specific Alkaline Phosphatase and Exercise. In: Preedy, V. (eds) Biomarkers in Bone Disease. Biomarkers in Disease: Methods, Discoveries and Applications. Springer, Dordrecht.

28. Rajab HA. The Effect of Vitamin D Level on Parathyroid Hormone and Alkaline Phosphatase. Diagnostics (Basel). 2022 Nov 17;12(11):2828. DOI: 10.3390/diagnostics12112828

29. Thacher TD, Sempos CT, Durazo-Arvizu RA, Fischer PR, Munns CF, Pettifor JM. The Validity of Serum Alkaline Phosphatase to Identify Nutritional Rickets in Nigerian Children on a Calcium-Deprived Diet. J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3559-e3564. DOI: 10.1210/clinem/dgab328.

30. Ray C. S, Singh B, Jena I, Behera S, Ray S. Low Alkaline Phosphatase (ALP) In Adult Population an Indicator of Zinc (Zn) and Magnesium (Mg) Deficiency. Curr Res Nutr Food Sci 2017;5(3). DOI: 10.12944/CRNFSJ.5.3.20.

31. Song, J., Fan, L., Shi, D. et al. Sleep and liver function biomarkers in relation to risk of incident liver cancer: a nationwide prospective cohort study. BMC Med 22, 261 (2024). DOI: 10.1186/s12916-024-03440-w.

32. Li Q, Zhang S, Wang H, Xue C, Zhang X, Qin S, Yuan J. Rotating night shift work, sleep duration and elevated gamma-glutamyl transpeptidase among steelworkers: cross-sectional analyses from a Chinese occupational cohort. BMJ Open. 2021 Dec 15;11(12):e053125. DOI: 10.1136/bmjopen-2021-053125.

33. Morselli L, Leproult R, Balbo M, Spiegel K. Role of sleep duration in the regulation of glucose metabolism and appetite. Best Pract Res Clin Endocrinol Metab. 2010 Oct;24(5):687-702. DOI: 10.1016/j.beem.2010.07.005.

34. Mathis SL, Farley RS, Fuller DK, Jetton AE, Caputo JL. The Relationship between Cortisol and Bone Mineral Density in Competitive Male Cyclists. J Sports Med (Hindawi Publ Corp). 2013;2013:896821. DOI: 10.1155/2013/896821.

35. von Känel R, Abbas CC, Begré S, Gander ML, Saner H, Schmid JP. Association between posttraumatic stress disorder following myocardial infarction and liver enzyme levels: a prospective study. Dig Dis Sci. 2010 Sep;55(9):2614-23. DOI: 10.1007/s10620-009-1082-z.

36. van Velsen EFS, Zervou Z, Zillikens MC. Serum alkaline phosphatase can be elevated in patients with hypophosphatasia due to liver disease. Eur J Med Genet. 2023 Nov;66(11):104866. DOI: 10.1016/j.ejmg.2023.104866.

37. Krishnamurthy VR, Baird BC, Wei G, Greene T, Raphael K, Beddhu S. Associations of serum alkaline phosphatase with metabolic syndrome and mortality. Am J Med. 2011 Jun;124(6):566.e1-7. DOI: 10.1016/j.amjmed.2010.11.030.

38. Al-Bashaireh AM, Haddad LG, Weaver M, Chengguo X, Kelly DL, Yoon S. The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms. J Osteoporos. 2018 Dec 2;2018:1206235. DOI: 10.1155/2018/1206235.

39. Sheng B, Li X, Nussler AK, Zhu S. The relationship between healthy lifestyles and bone health: A narrative review. Medicine (Baltimore). 2021 Feb 26;100(8):e24684. DOI: 10.1097/MD.0000000000024684.

40. Tsuang YH, Sun JS, Chen LT, Sun SC, Chen SC. Direct effects of caffeine on osteoblastic cells metabolism: the possible causal effect of caffeine on the formation of osteoporosis. J Orthop Surg Res. 2006 Oct 7;1:7. DOI: 10.1186/1749-799X-1-7.

41. Zhou Y, Guan XX, Zhu ZL, Guo J, Huang YC, Hou WW, Yu HY. Caffeine inhibits the viability and osteogenic differentiation of rat bone marrow-derived mesenchymal stromal cells. Br J Pharmacol. 2010 Dec;161(7):1542-52. DOI: 10.1111/j.1476-5381.2010.00998.x.

42. de Vries EM, Wang J, Leeflang MM, Boonstra K, Weersma RK, Beuers UH, Geskus RB, Ponsioen CY. Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value. Liver Int. 2016 Dec;36(12):1867-1875. DOI: 10.1111/liv.13110.

43. Rabiee A, Silveira MG. Primary sclerosing cholangitis. Transl Gastroenterol Hepatol. 2021 Apr 5;6:29. DOI: 10.21037/tgh-20-266.

44. Charoenngam N, Nasr A, Shirvani A, Holick MF. Hereditary Metabolic Bone Diseases: A Review of Pathogenesis, Diagnosis and Management. Genes (Basel). 2022 Oct 17;13(10):1880. DOI: 10.3390/genes13101880.

45. Bouchette P, Boktor SW. Paget Bone Disease. [Updated 2023 Nov 12].

46. Chane E, Wondifraw H, Hadgu R, Fasil A. Assessment of liver function tests of women taking hormonal contraceptives at University of Gondar comprehensive specialized hospital and Family Guidance Association of Gondar (FGAE), 2022; a comparative cross-sectional study. PLoS One. 2023 Aug 17;18(8):e0289746. DOI: 10.1371/journal.pone.0289746.

47. Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure. 2006 Apr;15(3):156-64. DOI: 10.1016/j.seizure.2005.12.009.

48. Lai CW, Jadhav S, Njei B, Ye A, Wactawski-Wende J, Mumford SL, Schisterman EF, Rotman Y. Rhythmic Fluctuations in Levels of Liver Enzymes During Menstrual Cycles of Healthy Women and Effects of Body Weight. Clin Gastroenterol Hepatol. 2020 Aug;18(9):2055-2063.e2. DOI: 10.1016/j.cgh.2019.11.047.

49. Jiang T, Zeng Q, He J. Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors? Transl Cancer Res. 2023 Oct 31;12(10):2932-2945. DOI: 10.21037/tcr-23-1190.

50. Lombardi G, Di Somma C, Rubino M, Faggiano A, Vuolo L, Guerra E, Contaldi P, Savastano S, Colao A. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics. J Endocrinol Invest. 2011 Jul;34(7 Suppl):18-22.

51. Gutch, Manish; Mandal, Uday Kumar1; Kumar, Sukriti2. Prediction of Rise in Alkaline Phosphatase at Different Vitamin D Levels. CHRISMED Journal of Health and Research 10(1):p 55-59, Jan–Mar 2023. DOI: 10.4103/2230-8210.342126.

52. Chen H, Li J, Wang Q. Associations between bone-alkaline phosphatase and bone mineral density in adults with and without diabetes. Medicine (Baltimore). 2018 Apr;97(17):e0432. DOI: 10.1097/MD.0000000000010432.